From April 25 to 29, 2024, the Zhongguancun Forum Annual Conference was held in Beijing, with the theme "Innovation: Building a Better World."
At this forum, major achievements in four key areas were highlighted: the cutting-edge frontier of global science and technology, the main economic battlefield, national strategic needs, and public health and people's lives. A series of world-class achievements and "cutting-edge technologies" innovations made their debut, including Nobel Laureate in Physiology or Medicine Barry Marshall sharing his views on "Curiosity-Driven Research," Fields Medalist Shing-Tung Yau discussing "Women and Scientific Development," and two Turing Award winners exploring the frontiers of artificial intelligence.
At this national and international event, AccuMedical's core product, the Lattice® Flow Diverter, was showcased alongside the latest high-end medical innovations in China, earning recognition and praise from national and municipal leaders.
Currently, AccuMedical holds over 100 domestic and international patents. Its neurointervention products cover all interventional devices and related access devices involved in the treatment of hemorrhagic and ischemic stroke. Six products have been approved and are rapidly progressing toward registration and commercialization.
With deep technical expertise and continuous innovation in the neurointervention field, AccuMedical was named a "Specialized, Refined, Featured, and Innovative" small and medium-sized enterprise in Beijing in 2022 and a National High-Tech Enterprise in 2023.
AccuMedical insists on integrating medicine and engineering to truly meet clinical patient needs. The Lattice® Flow Diverter is a new tool for the treatment of intracranial aneurysms, approved through the National Medical Products Administration's (NMPA) special review procedure for innovative medical devices. It is the first to expand the indication of flow diverters to treat small- and medium-sized vertebral artery aneurysms. It is now being used in many hospitals across China and has received high recognition from surgeons.
Intracranial aneurysms, often called the brain’s "ticking time bombs" have traditionally been treated through craniotomy, a procedure with high risks and long recovery time. The Lattice® Flow Diverter, with its material and structural innovations, has ushered intracranial aneurysm treatment into an easier “automatic era”.
Thanks to multiple groundbreaking innovations, the Lattice® Flow Diverter significantly enhances surgical efficacy and safety. Its mechanical balloon delivery system effectively minimizes vascular injury risks during procedures, ensures precise stent positioning, and achieves optimal wall apposition, thereby shortening surgery time and reducing complexity. Additionally, the MIROR surface modification technology effectively addresses issues with ischemic complications and cytotoxicity caused by metal oxides on woven stent surfaces, greatly improving surgical safety.
Clinical data highlights its effectiveness in improving patient outcomes: at 12 months post-surgery, the Lattice® Flow Diverter achieves a 91.4% success aneurysm occlusion rate and an in-stent restenosis rate of just 0.8%.
By greatly reducing the difficulty of treating past complex cases, the Lattice® Flow Diverter is making a significant contribution to improving public health and people's lives. This is the key significance of developing new quality productive forces in the medical field.
During an interview at the forum, AccuMedical’s CEO stated, “Developing new quality productive forces cannot simply be about benchmarking foreign products. AccuMedical aims to break the 'imitation-following' technological path and continue investing in innovative R&D to achieve ‘true innovation and practical use’ in the field of neurointerventional medical devices, continuing to produce better products to safeguard public health.”